Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Cell Cycle (Georgetown, Tex.)|August 23, 2008
Targeting the eIF4F translation initiation complex for cancer therapyBruce W Konicek, Chad A Dumstorf, Jeremy R Graff
Cancer Research|February 5, 2008
Targeting the eukaryotic translation initiation factor 4E for cancer therapyJeremy R Graff, Bruce W Konicek, Julia H Carter, et al.
Molecular Cancer Therapeutics|October 26, 2010
Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosisChad A Dumstorf, Bruce W Konicek, Ann M McNulty, et al.
Molecular Cancer Research : MCR|March 31, 2005
The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivationRebecca L Lynch, Bruce W Konicek, Ann M McNulty, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)Kim A Papp, Sascha Gerdes, Craig L Leonardi, et al.
Blood|March 20, 2013
Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursorsJessica K Altman, Amy Szilard, Bruce W Konicek, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis RegistryWayne P Gulliver, Kyoungah See, Baojin Zhu, et al.
The Journal of Investigative Dermatology|March 26, 2023
IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical PsoriasisScott A Ochsner, Mesias Pedroza, Rudolf T Pillich, et al.
Acta Dermato-Venereologica|September 5, 2024
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)April W Armstrong, Elisabeth Riedl, Patrick M Brunner, et al.
Dermatology and Therapy|November 4, 2022
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis RegistryBenjamin Lockshin, Ryan W Harrison, Robert R McLean, et al.
Pageof 2